Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Mauro Moroni, Silvio Marco Veronese, Silvia Benvenuti et al. · The Lancet Oncology · 2005
Cited by 941 works. doi:10.1016/s1470-2045(05)70102-9
Authors
- Silvio Marco Veronese
- Silvia Benvenuti
- Giovanna Marrapese
- Andrea Sartore Bianchi
- Federica Di Nicolantonio
- Marcello Gambacorta
- Salvatore Siena
- Alberto Bardelli
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
- Cancer genes and the pathways they control
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
- RAF/RAS oncogenes and mismatch-repair status
- Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers
- Prevalence of somatic alterations in the colorectal cancer cell genome
- Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer